Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made by Shanghai Haohai Biological Technology Co., Ltd.* (the "**Company**") pursuant to Rule 13.10B of the rules governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

Set out below for reference only is the announcement published by the Company on the website of the Shanghai Stock Exchange, titled "Shanghai Haohai Biological Technology Co., Ltd. Announcement on the Receipt of an Administrative Penalty Decision by One of the Company's Controlling Shareholders and De Facto Controllers for Matters Unrelated to the Company".

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Hou Yongtai
Chairman

Shanghai, the PRC, 23 December 2025

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie, Mr. Huang Ming and Mr. Wei Changzheng; and the independent non-executive directors of the Company are Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi and Mr. Yang Yushe.

* *For identification purpose only*

Stock Code: 688366 Stock Short Name: Haohai Biotec Announcement No.: 2025-052

Shanghai Haohai Biological Technology Co., Ltd.* Announcement on the Receipt of an Administrative Penalty Decision by One of the Company's Controlling Shareholders and De Facto Controllers for Matters Unrelated to the Company

The board of directors and all directors of the Company warrant that the content of this announcement does not contain any false records, misleading statements or material omissions, and accept responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

I. Basic Information

Shanghai Haohai Biological Technology Co., Ltd.* (the "Company") was informed that Mr. Jiang Wei, one of its controlling shareholders and de facto controllers, had previously received an Administrative Penalty Notice (Penalty Notice [2025] No. 67) issued by the China Securities Regulatory Commission (the "CSRC") in respect of matters unrelated to the Company. Details are set out in the announcement dated 17 September 2025 published on the website of the Shanghai Stock Exchange (www.sse.com.cn) under the title "Shanghai Haohai Biological Technology Co., Ltd. Announcement on the Receipt of an Administrative Penalty Notice by One of the Company's Controlling Shareholders and De Facto Controllers for Matters Unrelated to the Company" (Announcement No.: 2025-042).

Recently, the Company has been informed by Mr. Jiang Wei that he has received the Administrative Penalty Decision ([2025] No. 151) issued by the CSRC in respect of the aforementioned matters. The main content of the Administrative Penalty Decision is as follows: the CSRC has decided to confiscate the illegal gains of RMB4,709,741.41 from and impose a fine of RMB14,629,224.23 on Mr. Jiang Wei for insider trading and recommending securities trading to others.

II. Impact on the Company and Risk Alert

1. The subject of the Administrative Penalty Decision is Mr. Jiang Wei personally, and the matters involved are unrelated to the Company. Mr. Jiang Wei is not involved in the day-to-day management and operation of the Company, and the matter will not have a material impact on the day-to-day operation, business or financial position of the Company. As of the date of this announcement, the Company's production and operation activities are proceeding in an orderly manner as usual.

2. Information about the Company shall be subject to the announcements published by the Company on the designated information disclosure media and the website of the Shanghai Stock Exchange. Investors are advised to pay attention to investment risks.

The announcement is hereby made.

The board of directors of Shanghai Haohai Biological Technology Co., Ltd.*

24 December 2025